STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary
Amgen (NASDAQ:AMGN) has released its financial results for the third quarter of 2023. The company reported positive earnings and revenue growth compared to the same period last year. Amgen's strong performance was driven by increased sales of its key drugs, including Enbrel and Prolia. The company also announced progress in its pipeline, with several promising drug candidates in late-stage development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
-
Rhea-AI Summary
A large international study led by deCODE Genetics reveals new biological pathways for migraine treatment. The study analyzed genetic data from over 1.3 million participants and identified 44 variants associated with migraine, including 12 novel variants. The findings provide insights into the genetics and biology of migraine and could lead to the development of novel drug targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) will report its Q3 financial results on October 31, 2023, followed by a conference call with the investment community. The webcast will be available on Amgen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
Rhea-AI Summary
Amgen declares $2.13 per share dividend for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
dividends
-
Rhea-AI Summary
Amgen announces positive results from Phase 3 trial of LUMAKRAS in patients with KRAS G12C-mutated colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Amgen announces positive results for tarlatamab in patients with advanced small cell lung cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
Rhea-AI Summary
Amgen to host webcasted call for investment community following presentation of new data from oncology portfolio
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
-
Rhea-AI Summary
Amgen presents new data at ESMO Congress 2023, highlighting potential of various therapies in tough-to-treat cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
Rhea-AI Summary
Amgen completes acquisition of Horizon Therapeutics for $27.8 billion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
Rhea-AI Summary
deCODE Genetics scientists release findings from plasma proteomics study, demonstrating how it can contribute to understanding diseases. Associations found between diseases and specific proteins. Leveraging genetic factors can uncover molecular mechanisms of disease development. Data from 50,000 individuals analyzed using two platforms. Discrepancies between platforms affect biomarker discovery. Validation of individual assays necessary. deCODE is a global leader in genome analysis. Wholly-owned subsidiary of Amgen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $283.61 as of November 15, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 150.6B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

150.64B
536.44M
0.25%
81.23%
1.74%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS